Ultragenyx prices upsized IPO at $21, above the range

By
A A A

Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for rare metabolic genetic diseases, raised $121 million by offering 5.8 million shares at $21, above the range of $19 to $20. Ultragenyx Pharmaceutical plans to list on the NASDAQ under the symbol RARE. Ultragenyx Pharmaceutical initially filed confidentially on 10/4/2013. J.P. Morgan and Morgan Stanley acted as joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: RARE

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          

Stocks

Referenced

100%

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com